ClinicalTrials.gg
CompletedNCT02092922Updated Oct 19, 2020

A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

A Phase 2 interventional study of Filanesib, KSP (Eg5) inhibitor; intravenous and Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous in Advanced Multiple Myeloma, sponsored by Pfizer. Completed at 60 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-19.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma — 1 open to participants now, 1 under way, 1 of them phase 3. Granulocyte Colony-Stimulating Factor · Multiple Myeloma.

Enrollment
3rd of 28
154 · median 38
Started
2014
the only one that year
Phase 2
17 of 28
none open now
Registered
22nd of 28
by date
Lead sponsor
2 of 28
Pfizer

Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, this one is the 3rd largest by enrollment, is the only one that started in 2014, is one of 17 in phase 2, and was the 22nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, or all of them as a file.
02

Study summary

The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of filanesib in treating myeloma. Approximately 160 patients from North America and Europe will be enrolled in this study.

Eligible patients will have received at least two prior lines of therapy; have received prior bortezomib and lenalidomide; and have disease refractory to carfilzomib and/or pomalidomide.

03

Conditions studied

  • Advanced Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients with confirmed multiple myeloma whose treatment history must include all of the following:

    1. Received at least 2 (induction therapy and stem cell transplant ± maintenance are to be considered a single line of therapy).
    2. Received at least 2 cycles of a bortezomib-containing regimen and 2 cycles of a lenalidomide-containing regimen, unless intolerant to these agents (defined as requiring discontinuation due to toxicity).
    3. Disease to a carfilzomib-containing regimen and/or a pomalidomide containing regimen. Refractory is defined as either failure to achieve a minimal response (MR) or better while on therapy, or development of progressive disease (PD) while on therapy or within 60 days from last dose of therapy.
  • Measurable multiple myeloma disease, defined as meeting at least one of the following criteria within 14 days prior to first dose of study drug:

    1. A monoclonal Ig (M-protein) concentration on serum protein electrophoresis (SPEP) of ≥ 1.0 g/dL.
    2. Measurable urinary light chain secretion by quantitative analysis using urine protein electrophoresis (UPEP) of ≥ 200 mg/24 hours.
    3. Involved serum free light chain (FLC) level ≥ 10 mg/dL, provided the serum FLC ratio is abnormal.
  • (ECOG) performance status of 0, 1 or 2 within 14 days prior to first dose of study drug.
  • Adequate hematology, hepatic and renal function laboratory values within 14 days prior to first dose of study drug.
  • Additional criteria exist.

Key Exclusion Criteria:

  • Prior treatment with filanesib (ARRY-520) or any other KSP inhibitor.
  • Past or current plasma cell leukemia.
  • Primary amyloidosis (amyloidosis associated with multiple myeloma is allowed).
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes).
  • Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study drug.
  • Concomitant or previous malignancies (other than multiple myeloma) with less than a 2-year disease-free interval at the time of first dose of study drug. Patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or Stage 1 prostate cancer are eligible irrespective of the time of diagnosis.
  • Use of an agent that is not expected to be cleared by the time of first dose of study drug or that has been demonstrated to have prolonged side effects. Patients must have recovered from all side effects to a Grade 0 or 1 (except alopecia and neuropathy).
  • Any severe concurrent disease or condition (including severe , requirement for dialysis, symptomatic congestive heart failure [ Class III or IV], unstable angina pectoris, cardiac arrhythmia) which, in the judgment of the Investigator, would make the patient inappropriate for study participation.
  • Known positive serology for the (HIV), active and/or .
  • Acute active infection requiring treatment.
  • Additional criteria exist.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Filanesib

    Drug: Filanesib, KSP (Eg5) inhibitor; intravenous · Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Interventions

06

What researchers measure

Primary outcomes

  1. In patients with low Baseline alpha 1-acid glycoprotein (AAG), assess the efficacy of the study drug in terms of objective response rate.

    Time frame: up to 2 years

Secondary outcomes

  1. In patients with high Baseline AAG, assess the efficacy of the study drug in terms of objective response rate.

    Time frame: up to 2 years

  2. In all patients, assess the efficacy of the study drug in terms of duration of response.

    Time frame: up to 2 years

  3. In all patients, assess the efficacy of the study drug in terms of progression-free survival.

    Time frame: up to 2 years

  4. In all patients, assess the efficacy of study drug in terms of overall survival.

    Time frame: up to 2 years

  5. In all patients, assess the safety of the study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.

    Time frame: up to 2 years

  6. In a subset of all patients, characterize the pharmacokinetics (PK) of the study drug in terms of plasma concentration-time profiles.

    Time frame: 6 months

  7. In a subset of all patients, assess the correlation between study drug exposure and changes in corrected QT interval (QTc) in terms of changes in QTc versus time-matched study drug plasma concentrations.

    Time frame: 6 months

07

Study locations

60 sites
  • UAB Comprehensive Cancer Center
    Birmingham, Alabama 35249, United States
  • City of Hope
    Duarte, California 91010, United States
  • University of California, San Francisco Medical Center
    San Francisco, California 94143, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Yale Comprehensive Cancer Center
    New Haven, Connecticut 06510, United States
  • Emory University, Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Decatur Memorial Hospital
    Decatur, Illinois 62526, United States
  • University of Kansas Cancer Center and Medical Pavilion
    Westwood, Kansas 66205, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University in St. Louis
    Saint Louis, Missouri 63130, United States
  • Nebraska Hematology Oncology, P.C.
    Lincoln, Nebraska 68506, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • NY Presbyterian - Weill Cornell Medical Center
    New York, New York 10065, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Duke Cancer Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Cancer Care Northwest
    Spokane Valley, Washington 99216, United States
  • Institut Jules Bordet
    Bruxelles, Belgium
  • Universitaire Ziekenhuizen Leuven
    Leuven, Belgium
  • Tom Baker Cancer Centre
    Calgary, Alberta, Canada
  • QEII Health Sciences Center
    Halifax, Nova Scotia, Canada
  • Jewish General Hospital
    Montreal, Quebec, Canada
  • Centre Hospitalier Lyon-Sud
    Bierre-Benite Cedex, France
  • Hopital Claude Huriez
    Lille Cedex, France
  • Institut Paoli Calmettes
    Marseille Cedex 9, France
  • CHU Hotel Dieu
    Nantes Cedex, France
  • G.H.U Caremeau
    Nimes Cedex 9, France
  • Institut Universitaire de Cancer
    Toulouse, France
  • CHU tours-Hopital Bretonneau
    Tours Cedex, France
  • CHU de Nancy - Hopital de Brabois
    Vandoeuvre les Nancy, France
  • TU Dresden Medizinische Fakultat, Medizinische Klinik und Poliklinik I
    Dresden, Germany
  • Asklepios Kliniken Hamburg GmbH
    Hamburg, Germany
  • University Hospital Heidelberg
    Heidelberg, Germany
  • University Hospital Leipzig
    Leipzig, Germany
  • University of Tubingen
    Tubingen, Germany
  • Julius Maximilians Universitat Wurzburg
    Wurzburg, Germany
  • General Hospital of Athens "Evangelismos"
    Athens, Greece
  • University of Athens School of Medicine
    Athens, Greece
  • Hospital Germans Trias i Pujol
    Badalona, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, Spain
  • Hospital Universitario La Fe
    Valencia, Spain
  • Hospital Quiron de Zaragoza
    Zaragoza, Spain
  • Barts Health NHS Trust
    London, United Kingdom
  • Kings College Hospital NHS Foundation Trust
    London, United Kingdom
  • Southhampton General Hospital
    Southhampton, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    Surrey, United Kingdom
  • New Cross Hospital
    Wolverhampton, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Jul 2016, 26 months.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 26 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2014
First posted
Mar 20, 2014
StartActual
May 2014
Primary completionActual
Jul 2016
CompletionActual
Sep 5, 2017
Results delay requested
Aug 7, 2017
Last update
Oct 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02092922
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 20, 2014
Start date
May 2014
Primary completion
Jul 2016
Completion
Sep 5, 2017
Last update
Oct 19, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Filgrastim

Start the discussion